Posted Jan. 9, 2017 at 9:02 a.m.

BioCryst influenza treatment OK'd in Canada

Published: 2017-01-09 09:02:08
Updated: 2017-01-09 09:02:08

BioCryst Pharmaceuticals BioCryst Pharmaceuticals

RTP-based BioCryst Pharmaceuticals has received approval to sell its influenza treatment in Canada. It's now available in five countries.

BioCryst (Nasdaq: BCRX) announced the approval Sunday.

The company's treamtnet known as Rapivab is an  intravenous treatment for acute, uncomplicated influenza. It's already approved in the U.S.

The drug is being commercialized by BioCryst partner Seqirus.

Other partners are selling the drug in Japan, Taiwan and South Korea.

“This RAPIVAB approval represents an important milestone for BioCryst and for our partner, Seqirus,” said BioCryst CEO Jon Stonehouse. “We are excited that patients in Canada will soon have an I.V. option for the treatment of influenza infections.” 

BioCryst has a number of other treatments under development.

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders